Contact:
4008465777
Date：2021-06-30
Author：东宝
Views：183
On June 30, 2021, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (Dongbao Zixing), a wholly owned subsidiary of Tonghua Dongbao, introduced two novel gout (hyperuricemia) drugs - THDB130/THDB131 and THDB150/THDB151 - through technology transfer. The preclinical studies for the former have been completed, while that for the latter is still underway.
THDB130/THDB131 is expected to provide gout patients with a safer and more effective alternative to the existing therapies. THDB150/THDB151 has a good prospect for clinical application due to its special mechanism of action, which can both reduce uric acid production by inhibiting xanthine oxidase and increase uric acid excretion by inhibiting the urate transporters in the kidney.
According to the technology transfer contract, Dongbao Zixing will own the intellectual property rights of the above products worldwide and the related interests, and will be responsible for the subsequent clinical development, production, and commercialization of the products.
According to the Chinese Guidelines for the Treatment of Hyperuricemia and Gout (2019) and data from the 6th national population census conducted by the National Bureau of Statistics, the overall prevalence of hyperuricemia in China is 13.3%, with approximately 177 million patients, while the overall prevalence of gout is 1.1% with about 14.66 million patients. Hyperuricemia has become another common metabolic disease in China following diabetes, hypertension, and hyperlipidemia, with an obvious demand for clinical treatment and a promising market prospect.
Focused on pharmaceutical R&D for treating diabetes and other major endocrine diseases, Tonghua Dongbao will continue to promote technological innovation and improve its new drug R&D ability as China enacts policies to encourage drug innovation. The introduction of the two novel drugs marks Tonghua Dongbao’s official foray into gout treatment and continued expansion in the field of endocrine drugs.
Tonghua Dongbao will continue to keep a finger on the pulse of the cutting-edge and key technologies in diabetes and endocrine treatment, in a bid to build a world-class R&D and commercialization platform. Guided by the philosophy of "Establishing a Global Brand Through Consistent Innovation", the Company will vigorously advance technological innovation, inspire talent's creativity, and stick to the innovation-driven development strategy to promote high-quality business growth.
